Level Four Advisory Services LLC purchased a new position in shares of InMode Ltd. (NASDAQ:INMD – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,364 shares of the healthcare company’s stock, valued at approximately $299,000.
Other hedge funds have also bought and sold shares of the company. Millennium Management LLC increased its position in InMode by 78.2% in the fourth quarter. Millennium Management LLC now owns 1,916,711 shares of the healthcare company’s stock worth $68,427,000 after buying an additional 840,821 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of InMode by 23.2% in the first quarter. Renaissance Technologies LLC now owns 3,181,662 shares of the healthcare company’s stock valued at $117,435,000 after purchasing an additional 598,300 shares in the last quarter. Aureus Asset Management LLC purchased a new position in shares of InMode in the first quarter valued at $17,811,000. Lombard Odier Asset Management Switzerland SA purchased a new position in shares of InMode in the fourth quarter valued at $18,441,000. Finally, Norges Bank purchased a new position in shares of InMode in the fourth quarter valued at $16,839,000. 65.49% of the stock is currently owned by institutional investors.
InMode Stock Down 0.2 %
Shares of INMD stock opened at $33.91 on Tuesday. The business has a 50-day moving average price of $40.66 and a two-hundred day moving average price of $36.57. InMode Ltd. has a 12-month low of $26.10 and a 12-month high of $48.25. The firm has a market cap of $2.81 billion, a P/E ratio of 15.85 and a beta of 2.11.
Analysts Set New Price Targets
Several brokerages have recently weighed in on INMD. Canaccord Genuity Group lifted their price target on InMode from $47.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Barclays boosted their target price on InMode from $47.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 1st. Finally, Robert W. Baird boosted their target price on InMode from $53.00 to $61.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $51.67.
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
- Five stocks we like better than InMode
- How to Invest in Growth Stocks
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What Are Dividend Challengers?
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How to Evaluate a Stock Before Buying
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.